10 completed, 3 recruiting, 1 not yet recruiting, 1 unknown. 15 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 10, Recruiting 3, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Refractory Chronic Cough: new trials by email Literature Review of Refractory Chronic Cough trials Research Report on Refractory Chronic Cough
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough BCS+inactive, BCS+active - Chronic Cough (CC), Refractory Chronic Cough | Phase 2 | Recruiting | University of Montana | 135 | 2026-08-13 | 2026-08-18 |
| The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC) NAL ER, Placebo - Refractory Chronic Cough | Phase 2 | Recruiting | Trevi Therapeutics | 100 | 2026-06-22 | 2026-11-05 |
| A Phase 2 Study of HW091077 in Participants With Refractory Chronic Cough Or Unexplained Chronic Cough (RCC/UCC). HW091077, Matching placebo to HW091077 - Refractory Chronic Cough | Phase 2 | Not yet recruiting | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | 180 | 2026-05-01 | 2026-03-19 |
| A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough TCR1672 tablet - Refractory Chronic Cough | Phase 1 / Phase 2 | Unknown | Beijing Tide Pharmaceutical Co., Ltd | 72 | 2024-02-01 | 2024-01-19 |
| Refractory Chronic Cough Improvement Via NAL ER (RIVER) NAL ER, Placebo - Refractory Chronic Cough | Phase 2 | Completed | Trevi Therapeutics | 66 | 2023-11-30 | 2026-03-30 |
| A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough HRS-2261 oral tablet, Matching placebo to HRS-2261 - Refractory Chronic Cough | Phase 2 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 97 | 2023-03-09 | 2026-01-21 |
| Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough Duloxetine 30 MG, Duloxetine 60 MG, Amitriptyline 25 MG - Refractory Chronic Cough | Phase 2 | Recruiting | Mayo Clinic | 50 | 2021-11-01 | 2026-01-21 |
| Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough BLU-5937, Placebo - Refractory Chronic Cough | Phase 2 | Completed | Bellus Health Inc. - a GSK company | 310 | 2020-12-07 | 2021-12-13 |
| Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough 5 mg Serlopitant Tablets, Matching Placebo Tablets - Refractory Chronic Cough | Phase 2 | Completed | Vyne Therapeutics Inc. | 185 | 2017-10-03 | 2021-05-20 |
| An 8-Week Refractory Chronic Cough Study (MK-7264-021) Gefapixant, Placebo (for gefapixant) - Refractory Chronic Cough | Phase 2 | Completed | Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 24 | 2015-12-17 | 2019-11-25 |
| A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012) Gefapixant, Placebo (for gefapixant) - Refractory Chronic Cough | Phase 2 | Completed | Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 253 | 2015-12-15 | 2020-06-30 |
| Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014) Gefapixant 100 mg, Placebo - Refractory Chronic Cough | Phase 2 | Completed | Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 36 | 2015-10-28 | 2019-06-18 |
| Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015) Gefapixant, Placebo - Refractory Chronic Cough | Phase 2 | Completed | Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 50 | 2015-04-29 | 2021-02-12 |
| A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010) Gefapixant, Placebo (for gefapixant) - Refractory Chronic Cough | Phase 2 | Completed | Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 59 | 2015-03-09 | 2020-10-22 |
| Treatment of Refractory Chronic Cough With PA101 PA101, Placebo - Refractory Chronic Cough | Phase 2 | Completed | Patara Pharma | 52 | 2015-02-01 | 2016-02-22 |
Chronic Cough (15) · Cough (2) · Asthma (1) · Gastroesophageal Reflux (1) · cough hypersensitivity syndrome (1) · upper airway cough syndrome (1)
Pathological Conditions, Signs and Symptoms (15) · Respiration Disorders (15) · Respiratory Tract Diseases (15) · Signs and Symptoms (15) · Signs and Symptoms, Respiratory (15) · Cough (13) · Bronchial Diseases (1) · Deglutition Disorders (1) · Digestive System Diseases (1) · Esophageal Diseases (1) · Esophageal Motility Disorders (1) · Gastrointestinal Diseases (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1)
Gefapixant (5) · Nalbuphine (2) · Amitriptyline (1) · BLU-5937 (1) · Duloxetine Hydrochloride (1) · serlopitant (1)
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (5) · Trevi Therapeutics (2) · Beijing Tide Pharmaceutical Co., Ltd (1) · Bellus Health Inc. - a GSK company (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (1) · Mayo Clinic (1) · Patara Pharma (1) · University of Montana (1) · Vyne Therapeutics Inc. (1)
United Kingdom (6) · United States (5) · Canada (3) · China (1) · Czechia (1) · Germany (1) · Hungary (1) · Netherlands (1) · Poland (1)
Amanda Gillespie, PhD (1) · Jacky Smith (1) · Laurie J Slovarp, PhD (1) · Vivek N Iyer, MD (1)
PMID 28923239, PMID 31023843, PMID 31949115, PMID 32109425, PMID 33825965, PMID 34697975, PMID 35614875, PMID 36348054, PMID 40043302
2015 (4), 2017 (1)